Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. It is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). It has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).

• Revenue in USD (TTM)0.00
• Net income in USD-38.39m
• Incorporated2004
• Employees12.00

• Location
  Eledon Pharmaceuticals Inc19900 Macarthur Blvd Ste 550IRVINE 92612-8426United StatesUSA
• Phone+1 (949) 238-8090
• Fax+1 (302) 655-5049
• Websitehttps://eledon.com/